RxDoctor Payments Data

Tessa Janovsky, PA

Physician Assistant · Chandler, AZNPI 1538680079

Payments from drug & device makers

$9,067in general payments, 2019–2025

Across 247 payments — averaging $36.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$3K
  • Madrigal Pharmaceuticals$3K
  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$568
  • Intercept Pharmaceuticals, Inc.$431
  • Ipsen Biopharmaceuticals, Inc$235
  • plus $974 from 16 others

What the payments were for

  • Consulting fees$94010%
  • Speaking & faculty fees$1,35015%
  • Travel & lodging$501%
  • Food & beverage$6,61273%
  • Education$150%
  • Gifts$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,067 in reported general payments places this provider in the 95th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$44,545
Medicare patients
191
Services billed
558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpclusaSofosbuvir/Velpatasvir41$1,041,555
OcalivaObeticholic Acid14$144,008
XifaxanRifaximin30$108,943
RezdiffraResmetirom27$106,029
VemlidyTenofovir Alafenamide13$19,636
Ursodiol59$11,723
Lactulose44$1,266
Hydroxyzine Hcl12$210
Spironolactone15$199
Carvedilol27$178
Furosemide34$119
Prednisone13$26

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadEpclusa, Vemlidy$2,928$1,061,19154 claims
Intercept Pharmaceuticals, Inc.Ocaliva$431$144,00814 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$568$108,94330 claims
Madrigal PharmaceuticalsRezdiffra$2,621$106,02927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →